Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema.
A 28 year old man with asthma, bronchopulmonary aspergillosis, pulmonary thromboembolic disease, and pulmonary hypertension developed Aspergillus fumigatus empyema complicating a pneumothorax. His condition progressively deteriorated despite treatment with intravenous and intrapleural amphotericin B, but improved promptly after substituting nebulised liposomal amphotericin B and oral itraconazole. This experience suggests that nebulised liposomal amphotericin B is well tolerated and merits further assessment in the treatment of pulmonary fungal disease.
Purcell
I F
IF
Cardiothoracic Centre, Freeman Hospital, Newcastle-upon-Tyne, UK.
Corris
P A
PA
D000280:Administration, Inhalation; D000284:Administration, Oral; D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy*; D001232:Aspergillus fumigatus; D001249:Asthma / Q000150:complications; D004337:Drug Carriers; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use; D016724:Empyema, Pleural / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications; D017964:Itraconazole / Q000008:administration & dosage / Q000627:therapeutic use; D008081:Liposomes; D008297:Male; D009330:Nebulizers and Vaporizers; D011655:Pulmonary Embolism / Q000150:complications
D000935:Antifungal Agents; D004337:Drug Carriers; D008081:Liposomes; D017964:Itraconazole; D000666:Amphotericin B